For the worse-seeing eyes at baseline , the mean change in composite score with 0.3 mg ranibizumab at the 24-month visit was 1.0 more ( 95 % CI,-4 .7 to 6.7 ) than sham for RIDE patients and 1.8 more ( 95 % CI,-2 .7 to 6.2 ) than sham for RISE patients .